Table 1.
Laboratory findings at baseline, treatments and outcomes of dialysis cases
| Parameters | Case 1 | Case 2 | Case 3 | Case 4 |
| Age (yr) | 62 | 61 | 72 | 70 |
| Sex | Female | Male | Male | Male |
| BMI (kg/m2) | 17.9 | 20.9 | 19.4 | 22.3 |
| HCV genotype | 1b | 1b | 1b | 1b |
| Cause of dialysis | CGN | CGN | CGN | DM |
| IFN-based therapy: Outcome | PEG-IFN-α2a: partial response | Naive: NA | Naive: NA | Naive: NA |
| At the start of therapy | ||||
| HCV RNA (log10 IU/mL) | 4.7 | 6 | 6.3 | 4.9 |
| ALT (IU/L) | 54 | 18 | 36 | 19 |
| AST (IU/L) | 36 | 20 | 31 | 13 |
| WBC (cells/μL) | 1660 | 3780 | 4330 | 5200 |
| Hemoglobin (g/dL) | 10.5 | 11.3 | 12.4 | 11.6 |
| Platelets (cells/μL) | 72000 | 204000 | 146000 | 218000 |
| RAVs at baseline | D168E, Y93Y/H, Q80L | None | None | None |
| Severity of liver disease | Chronic hepatitis | Chronic hepatitis | Chronic hepatitis | Chronic hepatitis |
| Treatment and outcome | ||||
| Daclatasvir dosage (mg) | 60 | 60 | 60 | 60 |
| Asnaprevir dosage (mg) | 200 | 200 | 200 | 200 |
| Week of serum HCV RNA disappearance | 2 | 3 | 3 | 2 |
| Adherence to daclatasvir | 100%1 | 100% | 100% | 100% |
| Adherence to asnaprevir | 100%1 | 100% | 100% | 100% |
| Weeks of therapy | 9 | 24 | 24 | 24 |
| Response | Breakthrough | SVR12 | SVR12 | SVR12 |
| Adverse events | None | None | None | Heart failure, Pneumonitis, Myocardial ischemia |
1
The patient’s adherence to both drugs was 100% until the date of the discontinuation of the combination therapy. BMI: Body mass index; CGN: Chronic glomerulonephritis; DM: Diabetes mellitus; NA: Not applicable; HCV: Hepatitis C virus; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; WBC: White blood cells; RAVs: Resistance-associated variants; SVR: Sustained virological response.